47045-VEN-C-UNDP-1 The Global Fund to Fight AIDS, Tuberculosis and Malaria <narrative>HIV and TB prevention and care for key population in Venezuela. - Venezuela (Bolivarian Republic) (01-Jan-2024-31-Dec-2026)</narrative> Venezuela (Bolivarian Republic), TB/HIV, United Nations Development Programme Goals: Reducir los nuevos casos de VIH, con enfoque en las poblaciones clave/Reducing new HIV cases, focusing on key populations; Ampliar la cobertura y calidad del tratamiento antirretroviral, con énfasis en las poblaciones clave para el VIH/ Expand coverage and quality of antiretroviral treatment, with emphasis on key populations for HIV; Reducir de la carga de tuberculosis en todas sus formas entre las poblaciones vulnerables/ Reducing the burden of tuberculosis in all its forms among vulnerable populations; Asegurar la prevención, el abordaje y el tratamiento de la coinfección TB/VIH/ Ensure prevention, management and treatment of TB/HIV coinfection. Objectives: Facilitar el acceso de las poblaciones clave a los servicios de prevención y diagnóstico de VIH con participación comunitaria / Facilitate access of key populations to HIV prevention and diagnostic services with community participation; Asegurar el tratamiento antirretroviral continuado para todas las personas que lo necesiten, con énfasis en las poblaciones clave y en participación con la comunidad / Ensure continued antiretroviral treatment for all people in need, with emphasis on key populations and in partnership with the community; Reducir el estigma y la discriminación asociados al VIH y a las poblaciones clave, especialmente en los servicios de salud / Reduce stigma and discrimination associated with HIV and key populations, especially in health services; Fortalecer la vinculación de las poblaciones clave a servicios de atención de calidad para el VIH/Strengthen linkage of key populations to quality HIV care services; Fortalecer la oferta de servicios de prevención, diagnóstico y tratamiento de la tuberculosis en todas sus formas para las poblaciones vulnerables / Strengthen linkage of key populations to quality HIV care services; Asegurar el diagnóstico y la atención de calidad para las personas con TB-RR/MDR / Ensuring quality diagnosis and care for people with MDR/RR-TB; Implementar las actividades colaborativas entre los programas de VIH y de tuberculosis / Implement collaborative activities between HIV and tuberculosis programs. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme United Nations Development Programme The Global Fund to Fight AIDS, Tuberculosis and Malaria The Global Fund to Fight AIDS, Tuberculosis and Malaria Communications +41 58 791 1700 website@theglobalfund.org https://www.theglobalfund.org The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland The Global Fund to Fight AIDS, Tuberculosis and Malaria Grant Management Division Cecilia Vitale Fund Portfolio Manager +41 58 791 1700 cecilia.vitale@theglobalfund.org https://www.theglobalfund.org The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland Venezuela (Bolivarian Republic) HIV Multicomponent, RSSH Tuberculosis Ensure healthy lives and promote well-being for all at all ages End the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases, and combat hepatitis, water-borne diseases and other communicable diseases Achieve universal health coverage HIV -> Differentiated HIV Testing Services -> Community-based testing for KP programs HIV -> Differentiated HIV Testing Services -> Facility-based testing outside of key population (KP) and adolescent girls and young women (AGYW) programs HIV -> Prevention package for men who have sex with men (MSM) and their sexual partners -> Community empowerment for MSM HIV -> Prevention package for men who have sex with men (MSM) and their sexual partners -> Condom and lubricant programming for MSM HIV -> Prevention package for men who have sex with men (MSM) and their sexual partners -> HIV prevention communication, information and demand creation for MSM HIV -> Prevention package for men who have sex with men (MSM) and their sexual partners -> Pre-exposure prophylaxis (PrEP) programming for MSM HIV -> Prevention package for sex workers, their clients and other sexual partners -> Community empowerment for sex workers HIV -> Prevention package for sex workers, their clients and other sexual partners -> Condom and lubricant programming for sex workers HIV -> Prevention package for sex workers, their clients and other sexual partners -> HIV prevention communication, information and demand creation for sex workers HIV -> Prevention package for transgender people and their sexual partners -> Community empowerment for transgender people HIV -> Prevention package for transgender people and their sexual partners -> Condom and lubricant programming for transgender people HIV -> Prevention package for transgender people and their sexual partners -> HIV prevention communication, information and demand creation for transgender people HIV -> Prevention package for transgender people and their sexual partners -> Pre-exposure prophylaxis (PrEP) programming for transgender people HIV -> Reducing human rights-related barriers to HIV/TB services -> Improving laws, regulations and policies relating to HIV and HIV/TB HIV -> Reducing human rights-related barriers to HIV/TB services -> Reducing HIV-related gender discrimination, harmful gender norms and violence against women and girls in all their diversity HIV -> Treatment, care and support -> HIV treatment and differentiated service delivery - adults (15 and above) HIV -> Treatment, care and support -> HIV treatment and differentiated service delivery - children (under 15) HIV -> Treatment, care and support -> Treatment monitoring - Viral load and antiretroviral (ARV) toxicity Multicomponent -> Program management -> Coordination and management of national disease control programs Multicomponent -> Program management -> Grant management RSSH -> RSSH: Community systems strengthening -> Community-led monitoring RSSH -> RSSH: Monitoring and evaluation systems -> Analyses, evaluations, reviews and data use Tuberculosis -> Drug-resistant (DR)-TB diagnosis, treatment and care -> DR-TB diagnosis/drug susceptibility testing (DST) Tuberculosis -> Drug-resistant (DR)-TB diagnosis, treatment and care -> DR-TB treatment, care and support Tuberculosis -> Key and vulnerable populations (KVP) - TB/DR-TB -> KVP - Children and adolescents Tuberculosis -> Key and vulnerable populations (KVP) - TB/DR-TB -> KVP - Others Tuberculosis -> Key and vulnerable populations (KVP) - TB/DR-TB -> KVP - People in prisons/jails/detention centers Tuberculosis -> TB diagnosis, treatment and care -> TB screening and diagnosis Tuberculosis -> TB diagnosis, treatment and care -> TB treatment, care and support Tuberculosis -> TB/HIV -> TB/HIV - Screening, testing and diagnosis Tuberculosis -> TB/HIV -> TB/HIV - Treatment and care 4448735.55 4535333.06 10672862.46 9843940.50 Global Fund commitment to VEN-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 5523476.00 Global Fund disbursement to VEN-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 1477685.00 Global Fund disbursement to VEN-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 2842779.50 Global Fund disbursement to VEN-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 5498239.00 Global Fund commitment to VEN-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 4582989.00 Global Fund disbursement to VEN-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 3687751.00 Global Fund commitment to VEN-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme -915250.00 Global Fund commitment to VEN-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 3687751.00 Global Fund disbursement to VEN-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 1542250.50 Global Fund commitment to VEN-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 940458.50 Global Fund disbursement to VEN-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme -601792.00 Global Fund commitment to VEN-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 2369977.00 Global Fund commitment to VEN-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 2369977.00 Global Fund disbursement to VEN-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 4898171.71 Expenditure reported by United Nations Development Programme for VEN-C-UNDPP01, Jan 2024 to Dec 2024. United Nations Development Programme 4097123.42 Expenditure reported by United Nations Development Programme for VEN-C-UNDPP01, Jan 2025 to Dec 2025. United Nations Development Programme <narrative>Grant page on the data explorer of the Global Fund.</narrative> An overview of a grant over its lifetime. <narrative>Grant terms and conditions.</narrative> General terms and conditions which apply to Global Fund grants. <narrative>2023 - Funding Request - Window 1 - TB/HIV - Venezuela (Bolivarian Republic) - English</narrative> Funding Request of funding request FR1409-VEN-C. <narrative>2023 - Funding Request - Window 1 - TB/HIV - Venezuela (Bolivarian Republic) - Español</narrative> Funding Request of funding request FR1409-VEN-C. <narrative>Number of people with confirmed RR-TB and/or MDR-TB notified</narrative> Module: Drug-resistant (DR)-TB diagnosis, treatment and care. <narrative>Number of people with confirmed RR-TB and/or MDR-TB notified</narrative> Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative. Numerator: 84. Numerator: 82; Denominator: 84; Percentage: 97.62%. Numerator: 82; Denominator: 84; Percentage: 97.62%. Numerator: 2; Denominator: 84; Percentage: 2.38%. Numerator: 2; Denominator: 84; Percentage: 2.38%. Numerator: 52; Denominator: 84; Percentage: 61.9%. Numerator: 52; Denominator: 84; Percentage: 61.9%. Numerator: 32; Denominator: 84; Percentage: 38.1%. Numerator: 32; Denominator: 84; Percentage: 38.1%. Numerator: 82; Denominator: 84; Percentage: 97.62%. Numerator: 82; Denominator: 84; Percentage: 97.62%. Numerator: 2; Denominator: 84; Percentage: 2.38%. Numerator: 2; Denominator: 84; Percentage: 2.38%. Numerator: 0; Denominator: 84; Percentage: 0%. Numerator: 0; Denominator: 84; Percentage: 0%. Numerator: 75. Numerator: 150. Numerator: 121. Numerator: 75. Numerator: 63. Numerator: 118. Numerator: 3. Numerator: 43. Numerator: 78. Numerator: 113. Numerator: 8. Numerator: 0. Numerator: 200. Numerator: 84. Numerator: 100. Numerator: 100. Numerator: 51. Numerator: 50. Numerator: 1000. Numerator: 16. Numerator: 35. Numerator: 51. Numerator: 0. Numerator: 0. Numerator: 125. Numerator: 125. <narrative>Percentage of people with confirmed RR-TB and/or MDR-TB that began second-line treatment</narrative> Module: Drug-resistant (DR)-TB diagnosis, treatment and care. <narrative>Percentage of people with confirmed RR-TB and/or MDR-TB that began second-line treatment</narrative> Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative. Numerator: 82; Denominator: 84; Percentage: 97.62%. Numerator: 82; Denominator: 84; Percentage: 97.62%. Numerator: 2; Denominator: 84; Percentage: 2.38%. Numerator: 2; Denominator: 84; Percentage: 2.38%. Numerator: 32; Denominator: 84; Percentage: 38.1%. Numerator: 32; Denominator: 84; Percentage: 38.1%. Numerator: 68; Denominator: 84; Percentage: 80.95%. Numerator: 68; Denominator: 84; Percentage: 80.95%. Numerator: 52; Denominator: 84; Percentage: 61.9%. Numerator: 52; Denominator: 84; Percentage: 61.9%. Numerator: 16; Denominator: 84; Percentage: 19.05%. Numerator: 16; Denominator: 84; Percentage: 19.05%. Numerator: 84; Denominator: 84; Percentage: 100%. Numerator: 75; Denominator: 75; Percentage: 100%. Numerator: 150; Denominator: 150; Percentage: 100%. Numerator: 119; Denominator: 121; Percentage: 98.35%. Numerator: 75; Denominator: 75; Percentage: 100%. Numerator: 62; Denominator: 63; Percentage: 98.41%. Numerator: 116; Denominator: 118; Percentage: 98.31%. Numerator: 3; Denominator: 3; Percentage: 100%. Numerator: 42; Denominator: 43; Percentage: 97.67%. Numerator: 0. Numerator: 77; Denominator: 78; Percentage: 98.72%. Numerator: 119. Numerator: 200; Denominator: 200; Percentage: 100%. Numerator: 84; Denominator: 84; Percentage: 100%. Numerator: 100; Denominator: 100; Percentage: 100%. Numerator: 100; Denominator: 100; Percentage: 100%. Numerator: 51; Denominator: 51; Percentage: 100%. Numerator: 50; Denominator: 50; Percentage: 100%. Numerator: 1; Denominator: 1; Percentage: 100%. Numerator: 16; Denominator: 16; Percentage: 100%. Numerator: 0. Numerator: 35; Denominator: 35; Percentage: 100%. Numerator: 51. Numerator: 125; Denominator: 125; Percentage: 100%. Numerator: 125; Denominator: 125; Percentage: 100%. <narrative>Treatment success rate of RR-TB and/or MDR-TB: Percentage of patients with RR and/or MDR-TB successfully treated</narrative> Module: Drug-resistant (DR)-TB diagnosis, treatment and care. <narrative>Treatment success rate of RR-TB and/or MDR-TB: Percentage of patients with RR and/or MDR-TB successfully treated</narrative> Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative. Numerator: 23; Denominator: 34; Percentage: 67.65%. Numerator: 19; Denominator: 19; Percentage: 100%. Numerator: 19; Denominator: 19; Percentage: 100%. Numerator: 0; Denominator: 19; Percentage: 0%. Numerator: 0; Denominator: 19; Percentage: 0%. Numerator: 7; Denominator: 11; Percentage: 63.64%. Numerator: 7; Denominator: 11; Percentage: 63.64%. Numerator: 13; Denominator: 19; Percentage: 68.42%. Numerator: 13; Denominator: 19; Percentage: 68.42%. Numerator: 12; Denominator: 17; Percentage: 70.59%. Numerator: 12; Denominator: 17; Percentage: 70.59%. Numerator: 20; Denominator: 27; Percentage: 74.07%. Numerator: 20; Denominator: 27; Percentage: 74.07%. Numerator: 0; Denominator: 1; Percentage: 0%. Numerator: 0; Denominator: 1; Percentage: 0%. Numerator: 0. Numerator: 0. Numerator: 20; Denominator: 28; Percentage: 71.43%. Numerator: 20; Denominator: 28; Percentage: 71.43%. Numerator: 15; Denominator: 19; Percentage: 78.95%. Numerator: 15; Denominator: 19; Percentage: 78.95%. Numerator: 0; Denominator: 19; Percentage: 0%. Numerator: 0; Denominator: 19; Percentage: 0%. Percentage: 70%. Numerator: 67; Denominator: 84; Percentage: 79.76%. Percentage: 70%. Numerator: 67; Denominator: 84; Percentage: 79.76%. Numerator: 66. Numerator: 1. Numerator: 25; Denominator: 30; Percentage: 83.33%. Numerator: 9. Numerator: 41; Denominator: 54; Percentage: 75.93%. Numerator: 63. Numerator: 3. Numerator: 0. Numerator: 67; Denominator: 84; Percentage: 79.76%. Numerator: 56. Numerator: 0. Percentage: 70%. Numerator: 117; Denominator: 153; Percentage: 76.47%. Percentage: 70%. Numerator: 117; Denominator: 153; Percentage: 76.47%. Numerator: 60; Denominator: 77; Percentage: 77.92%. Numerator: 0; Denominator: 0. Numerator: 18; Denominator: 25; Percentage: 72%. Numerator: 0. Numerator: 42; Denominator: 52; Percentage: 80.77%. Numerator: 56; Denominator: 72; Percentage: 77.78%. Numerator: 4; Denominator: 5; Percentage: 80%. Numerator: 0; Denominator: 0. Numerator: 60; Denominator: 77; Percentage: 77.92%. Numerator: 60. Numerator: 0; Denominator: 0. Percentage: 70%. <narrative>Number of people with TB (all forms) notified among prisoners; *includes only those with new and relapse TB</narrative> Module: Key and vulnerable populations (KVP) - TB/DR-TB. <narrative>Number of people with TB (all forms) notified among prisoners; *includes only those with new and relapse TB</narrative> Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative. <narrative>Number of patients with of all forms of TB notified (i.e., bacteriologically confirmed + clinically diagnosed); *includes only those with new and relapse TB</narrative> Module: TB diagnosis, treatment and care. <narrative>Number of patients with of all forms of TB notified (i.e., bacteriologically confirmed + clinically diagnosed); *includes only those with new and relapse TB</narrative> Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative. Numerator: 9865. Numerator: 9358; Denominator: 9865; Percentage: 94.86%. Numerator: 9358; Denominator: 9865; Percentage: 94.86%. Numerator: 507; Denominator: 9865; Percentage: 5.14%. Numerator: 507; Denominator: 9865; Percentage: 5.14%. Numerator: 7294; Denominator: 9865; Percentage: 73.94%. Numerator: 7294; Denominator: 9865; Percentage: 73.94%. Numerator: 3761; Denominator: 9865; Percentage: 38.12%. Numerator: 3761; Denominator: 9865; Percentage: 38.12%. Numerator: 6104; Denominator: 9865; Percentage: 61.88%. Numerator: 6104; Denominator: 9865; Percentage: 61.88%. Numerator: 4450; Denominator: 9865; Percentage: 45.11%. Numerator: 4450; Denominator: 9865; Percentage: 45.11%. Numerator: 426; Denominator: 9865; Percentage: 4.32%. Numerator: 426; Denominator: 9865; Percentage: 4.32%. Numerator: 4989; Denominator: 9865; Percentage: 50.57%. Numerator: 4989; Denominator: 9865; Percentage: 50.57%. Numerator: 11128. Numerator: 10641. Numerator: 5564. Numerator: 5564. Numerator: 5325. Numerator: 9989. Numerator: 652. Numerator: 8143. Numerator: 3890. Numerator: 6751. Numerator: 6688. Numerator: 578. Numerator: 3375. Numerator: 5925. Numerator: 11850. Numerator: 10805. Numerator: 5925. Numerator: 5873. Numerator: 5493. Numerator: 380. Numerator: 4636. Numerator: 2126. Numerator: 3747. Numerator: 3839. Numerator: 310. Numerator: 1714. Numerator: 6246. Numerator: 6246. <narrative>Percentage of new and relapse TB patients tested using WHO recommended rapid diagnostic tests at the time of diagnosis</narrative> Module: TB diagnosis, treatment and care. <narrative>Percentage of new and relapse TB patients tested using WHO recommended rapid diagnostic tests at the time of diagnosis</narrative> Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative. Numerator: 424; Denominator: 9090; Percentage: 4.66%. Numerator: 424; Denominator: 9090; Percentage: 4.66%. Numerator: 1120; Denominator: 9865; Percentage: 11.35%. Numerator: 683; Denominator: 5689; Percentage: 12.01%. Numerator: 2048; Denominator: 11378; Percentage: 18%. Numerator: 6544; Denominator: 10641; Percentage: 61.5%. Numerator: 1365; Denominator: 5689; Percentage: 23.99%. Numerator: 4176; Denominator: 5325; Percentage: 78.42%. Numerator: 5883. Numerator: 5082; Denominator: 12100; Percentage: 42%. Numerator: 6238; Denominator: 10805; Percentage: 57.73%. Numerator: 2178; Denominator: 6050; Percentage: 36%. Numerator: 2904; Denominator: 6050; Percentage: 48%. Numerator: 3460; Denominator: 5873; Percentage: 58.91%. Numerator: 3137. Numerator: 3823; Denominator: 6371; Percentage: 60.01%. Numerator: 4587; Denominator: 6371; Percentage: 72%. <narrative>Treatment success rate- all forms: Percentage of patients with all forms of TB, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all TB patients notified during a specified period; *includes only those with new and relapse TB</narrative> Module: TB diagnosis, treatment and care. <narrative>Treatment success rate- all forms: Percentage of patients with all forms of TB, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all TB patients notified during a specified period; *includes only those with new and relapse TB</narrative> Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative. Numerator: 7681; Denominator: 9090; Percentage: 84.5%. Numerator: 7404; Denominator: 7681; Percentage: 96.39%. Numerator: 7404; Denominator: 7681; Percentage: 96.39%. Numerator: 277; Denominator: 7681; Percentage: 3.61%. Numerator: 277; Denominator: 7681; Percentage: 3.61%. Numerator: 2696; Denominator: 7681; Percentage: 35.1%. Numerator: 2696; Denominator: 7681; Percentage: 35.1%. Numerator: 4985; Denominator: 7681; Percentage: 64.9%. Numerator: 4985; Denominator: 7681; Percentage: 64.9%. Numerator: 3528; Denominator: 7681; Percentage: 45.93%. Numerator: 3528; Denominator: 7681; Percentage: 45.93%. Numerator: 265; Denominator: 7681; Percentage: 3.45%. Numerator: 265; Denominator: 7681; Percentage: 3.45%. Numerator: 3888; Denominator: 7681; Percentage: 50.62%. Numerator: 3888; Denominator: 7681; Percentage: 50.62%. Numerator: 8551; Denominator: 10060; Percentage: 85%. Numerator: 4360; Denominator: 4939; Percentage: 88.28%. Numerator: 4275.5; Denominator: 5030; Percentage: 85%. Numerator: 4275.5; Denominator: 5030; Percentage: 85%. Numerator: -126; Denominator: -287; Percentage: 43.9%. Numerator: 4109. Numerator: 256. Numerator: 1554. Numerator: 2791. Numerator: 2166. Numerator: 168. Numerator: 2026. Numerator: 9681.4; Denominator: 11128; Percentage: 87%. Numerator: 9292; Denominator: 10813; Percentage: 85.93%. Numerator: 4840.68; Denominator: 5564; Percentage: 87%. Numerator: 4840.68; Denominator: 5564; Percentage: 87%. Numerator: 2731; Denominator: 3047; Percentage: 89.63%. Numerator: 4343; Denominator: 5009; Percentage: 86.7%. Numerator: 284; Denominator: 327; Percentage: 86.85%. Numerator: 1778; Denominator: 2011; Percentage: 88.41%. Numerator: 2849; Denominator: 3325; Percentage: 85.68%. Numerator: 3016; Denominator: 3367; Percentage: 89.58%. Numerator: 246; Denominator: 310; Percentage: 79.35%. Numerator: 1365; Denominator: 1659; Percentage: 82.28%. Numerator: 5332.5; Denominator: 5925; Percentage: 90%. Numerator: 5332.5; Denominator: 5925; Percentage: 90%. <narrative>Percentage of HIV-positive new and relapse TB patients on ART during TB treatment</narrative> Module: TB/HIV. <narrative>Percentage of HIV-positive new and relapse TB patients on ART during TB treatment</narrative> Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative. Numerator: 410; Denominator: 426. Numerator: 410; Denominator: 426. Numerator: 12; Denominator: 426. Numerator: 12; Denominator: 426. Numerator: 4; Denominator: 426. Numerator: 4; Denominator: 426. Numerator: 121; Denominator: 426. Numerator: 121; Denominator: 426. Numerator: 305; Denominator: 426. Numerator: 305; Denominator: 426. Numerator: 426; Denominator: 426. Numerator: 422; Denominator: 578. Numerator: 280; Denominator: 333. Numerator: 395; Denominator: 552. Numerator: 20; Denominator: 17. Numerator: 7; Denominator: 9. Numerator: 144; Denominator: 156. Numerator: 418; Denominator: 422. Numerator: 518; Denominator: 548. Numerator: 283; Denominator: 304. Numerator: 486; Denominator: 516. Numerator: 18; Denominator: 18. Numerator: 14; Denominator: 14. Numerator: 120; Denominator: 127. Numerator: 398; Denominator: 421. <narrative>Percentage of people living with HIV currently enrolled on antiretroviral therapy who started TB preventive treatment (TPT) during the reporting period</narrative> Module: TB/HIV. <narrative>Percentage of people living with HIV currently enrolled on antiretroviral therapy who started TB preventive treatment (TPT) during the reporting period</narrative> Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative - special. Numerator: 123; Denominator: 60765; Percentage: 0.2%. Numerator: 121; Denominator: 123; Percentage: 98.37%. Numerator: 121; Denominator: 123; Percentage: 98.37%. Numerator: 0; Denominator: 123; Percentage: 0%. Numerator: 0; Denominator: 123; Percentage: 0%. Numerator: 22; Denominator: 123; Percentage: 17.89%. Numerator: 22; Denominator: 123; Percentage: 17.89%. Numerator: 0; Denominator: 123; Percentage: 0%. Numerator: 0; Denominator: 123; Percentage: 0%. Numerator: 2; Denominator: 123; Percentage: 1.63%. Numerator: 2; Denominator: 123; Percentage: 1.63%. Numerator: 101; Denominator: 123; Percentage: 82.11%. Numerator: 101; Denominator: 123; Percentage: 82.11%. Numerator: 0; Denominator: 123; Percentage: 0%. Numerator: 0; Denominator: 123; Percentage: 0%. Numerator: 22; Denominator: 123; Percentage: 17.89%. Numerator: 22; Denominator: 123; Percentage: 17.89%. Numerator: 101; Denominator: 123; Percentage: 82.11%. Numerator: 101; Denominator: 123; Percentage: 82.11%. Numerator: 0; Denominator: 123; Percentage: 0%. Numerator: 0; Denominator: 123; Percentage: 0%. Numerator: 900; Denominator: 72533; Percentage: 1.2%. Numerator: 646; Denominator: 57484; Percentage: 1.12%. Numerator: 450; Denominator: 69270.5; Percentage: 0.65%. Numerator: 450; Denominator: 72533; Percentage: 0.62%. Numerator: 320; Denominator: 57484; Percentage: 0.56%. Numerator: 633. Numerator: 0. Numerator: 460. Numerator: 4. Numerator: 9. Numerator: 182. Numerator: 4. Numerator: 172. Numerator: 474. Numerator: 0. Numerator: 600; Denominator: 73627.5; Percentage: 0.81%. Numerator: 1200; Denominator: 74722; Percentage: 1.6%. Numerator: 685; Denominator: 66815; Percentage: 1.03%. Numerator: 600; Denominator: 74722; Percentage: 0.8%. Numerator: 379; Denominator: 66815; Percentage: 0.57%. Numerator: 369. Numerator: 0. Numerator: 365. Numerator: 4. Numerator: 4. Numerator: 9. Numerator: 6. Numerator: 80. Numerator: 299. Numerator: 1. Numerator: 1050; Denominator: 75817.5; Percentage: 1.38%. Numerator: 1050; Denominator: 76913; Percentage: 1.37%. <narrative>Percentage of adults (15 and above) on ART among all adults living with HIV at the end of the reporting period</narrative> Module: Treatment, care and support. <narrative>Percentage of adults (15 and above) on ART among all adults living with HIV at the end of the reporting period</narrative> Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative - other. Numerator: 15264; Denominator: 59749. Numerator: 15264; Denominator: 59749. Numerator: 44485; Denominator: 59749. Numerator: 44485; Denominator: 59749. Numerator: 57484; Denominator: 110000. Numerator: 68070.5; Denominator: 100301. Numerator: 71333; Denominator: 100301. Numerator: 56697; Denominator: 100301. Numerator: 71333; Denominator: 100301. Numerator: 56697; Denominator: 100301. Numerator: 14944; Denominator: 28205. Numerator: 41753; Denominator: 71675. Numerator: 64271; Denominator: 110000. Numerator: 66109; Denominator: 110000. Numerator: 72427.5; Denominator: 107133. Numerator: 64271; Denominator: 110000. Numerator: 66109; Denominator: 110000. Numerator: 16763; Denominator: 65942. Numerator: 49179; Denominator: 65942. Numerator: 65367; Denominator: 113000. Numerator: 66462; Denominator: 113000. <narrative>Percentage of children (under 15) on ART among all children living with HIV at the end of the reporting period</narrative> Module: Treatment, care and support. <narrative>Percentage of children (under 15) on ART among all children living with HIV at the end of the reporting period</narrative> Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative - other. Numerator: 452; Denominator: 1016. Numerator: 452; Denominator: 1016. Numerator: 564; Denominator: 1016. Numerator: 564; Denominator: 1016. Numerator: 787; Denominator: 2900. Numerator: 1200; Denominator: 3416. Numerator: 1200; Denominator: 3416. Numerator: 787; Denominator: 3416. Numerator: 1200; Denominator: 3416. Numerator: 787; Denominator: 3416. Numerator: 368; Denominator: 1832. Numerator: 419; Denominator: 1932. Numerator: 1200; Denominator: 3438. Numerator: 1000; Denominator: 2900. Numerator: 873; Denominator: 2900. Numerator: 1000; Denominator: 2900. Numerator: 873; Denominator: 2900. Numerator: 417; Denominator: 873. Numerator: 456; Denominator: 873. Numerator: 1000; Denominator: 2750. Numerator: 1000; Denominator: 2750.